Patented nicotinamide riboside launched by Chromadex

ChromaDex Corporation® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the launch of NIAGEN™, its novel, patented, branded nicotinamide riboside (NR).

ChromaDex's NIAGEN™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

NIAGEN™ may have tremendous appeal to the approximately 150 million Americans who are obese or over weight as well as the 75 million aging baby boomers in the U.S. – both of which are actively seeking new dietary supplement solutions for obesity or healthy aging.  These large segments of the U.S. population continue to fuel the growing multi-billion dollar dietary supplement markets.

NIAGEN™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University.  ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.

Frank Jaksch , Founder and CEO, states "By solving the immense challenge of producing NR on a commercially viable scale, we have achieved the first step in unlocking the potential of this new vitamin. The formal launch of NIAGEN™, our branded nicotinamide riboside, will immediately allow dietary supplement, and food & beverage companies to include NIAGEN™ in product formulations.   

Jaksch continues, "We are in the final stages of completing the design of our first human clinical study for NIAGEN™.  Additionally, we continue to collaborate with several universities and research institutes who have ongoing research activities designed to validate the tremendous health benefits of NR as well as create a strong commercial platform of health claims." 




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Supplementing diet with amino acid taurine could be a viable nutritional strategy to combat aging